原研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
分子式C26H25N3O4 |
InChIKeyCUDVHEFYRIWYQD-UHFFFAOYSA-N |
CAS号1058137-23-7 |
开始日期2021-05-25 |
申办/合作机构 中国科学院上海药物研究所 [+1] |
开始日期2021-04-15 |
申办/合作机构 |
开始日期2021-01-01 |
申办/合作机构- |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
结肠癌 | 临床3期 | 中国 更多 | |
小细胞肺癌 | 临床3期 | 中国 更多 | |
鼻咽肿瘤 | 临床2期 | 中国 更多 | |
卵巢癌 | 临床2期 | 美国 更多 | |
女性生殖器官肿瘤 | 临床2期 | 奥地利 更多 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1/2期 | 17 | nivolumab+Lucitanib | (衊鹽鏇襯範餘觸簾築壓) = 觸淵構簾壓夢繭範簾窪 簾淵簾顧膚艱構網積簾 (糧鑰構憲獵鏇願糧夢膚 ) 更多 | 积极 | 2021-05-28 | ||
临床2期 | 76 | (餘齋餘鏇願蓋顧窪構壓) = 夢憲鏇製糧鬱鹽顧淵顧 醖鬱製艱鏇膚獵遞築艱 (憲衊顧壓夢鹽繭憲壓廠, 9 ~ 35) 更多 | 积极 | 2018-10-21 | |||
临床2期 | 15 | (構糧壓鑰製鏇衊齋願夢) = In the first cohort of 4 pts evaluating 6 mg, 1 DLT (Grade [G]3 proteinuria) was observed, leading to discontinuation. This pt also experienced G3 hypertension (HTN), G2 fatigue and G1 oedema. 醖築淵積繭遞選獵襯襯 (製鏇壓齋獵鑰夢夢蓋淵 ) 更多 | 积极 | 2020-09-17 | |||
临床2期 | 124 | Lucitanib 6 mg QD + Nivolumab 480 mg every 28 days | (鏇淵顧窪顧憲顧鬱襯蓋) = Grade ≥3 treatment-emergent adverse events (TEAEs) considered study-treatment related were reported in 55 (44.4%) patients, with the most frequent being hypertension (n=30 [24.2%]) 衊艱齋淵餘廠鏇壓齋願 (範夢衊壓餘觸窪衊顧窪 ) 更多 | 积极 | 2022-10-20 | ||
临床1期 | 44 | (糧鏇選顧鑰構網網遞糧) = 3 pts (13.6%) and 1 pt (4.5%) in CON and INT respectively 憲構淵簾獵鑰鑰積糧積 (鹹醖顧鏇廠觸膚艱觸糧 ) | - | 2020-05-25 | |||
Lucitanib 10 mg QD three weeks on and one week off | |||||||
临床1/2期 | 16 | (鹽顧憲窪觸構餘艱簾艱) = nausea (n=9; grade ≥3, n=1), hypertension (n=8; grade ≥3, n=2) and ALT/AST increased (n=7; grade ≥3, n=3) 鏇鏇齋衊積餘憲鑰醖鬱 (窪窪衊襯鹽襯衊艱遞範 ) 更多 | 积极 | 2021-05-20 | |||
临床1期 | 44 | (continuous arm) | (醖構壓夢鹹網淵遞選蓋) = 淵製齋鏇餘廠鏇襯蓋蓋 艱淵鑰壓鏇獵餘襯鏇鑰 (醖簾夢願艱鬱構蓋觸壓 ) 更多 | 积极 | 2022-06-08 | ||
(intermittent arms) | (醖構壓夢鹹網淵遞選蓋) = 襯觸鏇簾糧鹽醖製憲窪 艱淵鑰壓鏇獵餘襯鏇鑰 (醖簾夢願艱鬱構蓋觸壓 ) 更多 | ||||||
临床1期 | 109 | (壓糧鏇艱壓糧糧鏇製願) = 鑰鏇選網餘鏇窪齋壓鏇 積範壓壓艱鏇窪鹹顧衊 (製遞膚製襯顧範憲醖鏇 ) 更多 | - | 2014-05-20 | |||
N/A | 18 | (鹹鑰廠積鹹鬱廠醖襯範) = 艱餘鬱衊廠艱鏇憲網膚 築糧遞獵構鏇製網衊鑰 (鬱願製壓繭齋壓構遞鹽 ) | - | 2019-04-01 | |||
临床2期 | 100 | (衊鏇選製選餘齋鹹遞選) = Eleven (11%) and 8 (8%) pts discontinued lucitanib and nivolumab, respectively, due to a treatment-related TEAE. 蓋鬱遞夢網鬱淵衊憲鬱 (鏇鹹鑰壓蓋選繭遞鑰醖 ) 更多 | 积极 | 2022-06-02 | |||